CTOs on the Move

PanTheryx

www.pantheryx.com

 
PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.pantheryx.com
  • 5480 Valmont Road Suite 325
    Boulder, CO USA 80301
  • Phone: 303.951.6883

Executives

Name Title Contact Details

Funding

PanTheryx raised $53M on 03/30/2016
PanTheryx raised $50M on 06/27/2019

Similar Companies

Acreage Holdings

Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company`s national retail store ‎brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ‎seamless, consumer-focused, branded experience.

Immune Pharmaceuticals

Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Novis Pharmaceuticals

Novis Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centrix Pharmaceutical

Centrix Pharmaceutical is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RedHill Biopharma

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force of approximately 40 sales representatives promoting two speciality gastrointestinal products in select U.S. territories. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise. '